A Phase 1 interventional study of collagenase clostridium histolyticum in Dupuytren's Contracture, sponsored by Endo Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-10-05.
Sponsored by Endo Pharmaceuticals (part of Keenova Therapeutics plc) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing Microbial Collagenase in Dupuytren Contracture — none open to participants now, 1 under way, none of them phase 3. Microbial Collagenase · Dupuytren Contracture.
Among the 17 studies testing Microbial Collagenase in Dupuytren Contracture, this one is the 15th largest by enrollment, is one of 2 that started in 2007, is the only one in phase 1, and was the 2nd registered.
78 studies on the registry are indexed under Dupuytren Contracture; 18 are open to participants now.
Browse Dupuytren Contracture studies →None of the 17 studies testing Microbial Collagenase in Dupuytren Contracture is open now. The open studies under Dupuytren Contracture, anywhere →
Microbial Collagenase: first FDA approval 1965 (SANTYL), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 12 Dupuytren Contracture studies recruiting now, 10 (83%) set no upper age limit and 1 (8%) stops at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2007.
This study's enrollment of 16 is below the median of 72 across 57 interventional studies indexed under Dupuytren Contracture.
Median enrollment 76 across the 17 interventional studies. Of the 15 that completed or were terminated, 12 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 17 have an industry lead sponsor. The 10 most frequent:
This study is registered under Endo Pharmaceuticals, one of the names counted as Keenova Therapeutics plc. Under that name alone:
Endo Pharmaceuticals is the lead sponsor of 99 studies on the registry; none are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 14 (88%) have results posted.
10 studies in Dupuytren Contracture by Keenova Therapeutics plc: none open now, none under way, none of them phase 3. Of 10 finished, 6 (60%) have results posted.
Among the 10 studies in Dupuytren Contracture by Keenova Therapeutics plc, this one is one of 2 that started in 2007, is the only one in phase 1, and was the 1st registered.
Keenova Therapeutics plc’s Dupuytren Contracture studies by the year they started, since 2007.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing Microbial Collagenase in Dupuytren Contracture, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Keenova Therapeutics plc’s 10 in Dupuytren Contracture:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A Phase 1, open-label, single-dose pharmacokinetic study in subjects with Dupuytren's contracture conducted at one site in the United States. All subjects received a single dose of AA4500 0.58 mg, which was injected directly into the cord affecting either the metacarpophalangeal (MP) or proximal interphalangeal (PIP) joint. Pharmacokinetic blood samples were collected before dosing, at predetermined time points through the 24 hours after dosing, Day 7, and Day 30. Efficacy and safety assessments were performed up to 30 days after the AA4500 0.58 injection.
This study was designed to be part of the larger clinical program, for adult patients with Dupuytren's contracture with a palpable cord, where the data from 2 pivotal Placebo-Controlled studies (AUX-CC-857 [NCT00528606]and AUX-CC-859 [NCT00533273]) and 7 non-pivotal studies were evaluated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Biological: collagenase clostridium histolyticum
Single dose of AA4500 0.58 mg into the cord
Also known as: XIAFLEX®, AA4500
Number of Subjects With AUX I and AUX II Detected in Their Blood After a Single Dose of AA4500
AUX I and AUX II are the constituent protein collagenases of collagenase clostridium histolyticum (AA4500). Plasma concentrations of AUX I and AUX II were assessed through an enzymye-linked-immunoabsorbent assay (ELISA).
Time frame: Before dosing, at predetermined time points through the 24 hours after dosing, Day 7, and Day 30
Clinical Success
Clinical success defined as a reduction in contracture (ie, flexion deformity) to ≤5° of normal as measured by finger goniometry 30 days after an injection. Last observation carried forward (LOCF) after the injection was used if the status at day 30 could not be determined.
Time frame: 30 days after treatment to the primary joint
Clinical Improvement
Clinical improvement defined as ≥50% reduction from baseline in contracture within 30 days of the injection. LOCF after the injection was used if the status at day 30 could not be determined.
Time frame: 30 days after treatment to the primary joint
Percent Change From Baseline Contracture
Change from baseline in the degree of fixed-flexion contracture calculated as 100 times (baseline contracture minus last available post-injection contracture measurement) divided by baseline contracture where a positive change indicates a reduction in the degree of contracture.
Time frame: Baseline, 30 days after treatment to the primary joint
Change From Baseline Range of Motion
Range of motion defined as the difference between the finger extension angle and finger flexion angle expressed in degrees
Time frame: Baseline, 30 days after treatment to the primary joint
| Milestone | AA4500 0.58 mg |
|---|---|
| Started | 16 |
| Completed | 15 |
| Not completed | 1 |
| Withdrew: Lost to follow-up | 1 |
AUX I and AUX II are the constituent protein collagenases of collagenase clostridium histolyticum (AA4500). Plasma concentrations of AUX I and AUX II were assessed through an enzymye-linked-immunoabsorbent assay (ELISA).
| participants | AA4500 0.58 mg |
|---|---|
| Number of Subjects With AUX I and AUX II Detected in Their Blood After a Single Dose of AA4500 | 0 |
Clinical success defined as a reduction in contracture (ie, flexion deformity) to ≤5° of normal as measured by finger goniometry 30 days after an injection. Last observation carried forward (LOCF) after the injection was used if the status at day 30 could not be determined.
| Percentage of joints | AA4500 0.58 mg |
|---|---|
| Clinical Success | 75.0 |
Clinical improvement defined as ≥50% reduction from baseline in contracture within 30 days of the injection. LOCF after the injection was used if the status at day 30 could not be determined.
| Percentage of joints | AA4500 0.58 mg |
|---|---|
| Clinical Improvement | 100.0 |
Change from baseline in the degree of fixed-flexion contracture calculated as 100 times (baseline contracture minus last available post-injection contracture measurement) divided by baseline contracture where a positive change indicates a reduction in the degree of contracture.
| Percentage of contracture change | AA4500 0.58 mg |
|---|---|
| Percent Change From Baseline Contracture | 91.6 ± 16.57 |
Range of motion defined as the difference between the finger extension angle and finger flexion angle expressed in degrees
| Degrees | AA4500 0.58 mg |
|---|---|
| Change From Baseline Range of Motion | 39.1 ± 15.38 |
Collected over From the time that the first dose of study drug was administered until 30 days elapsed following discontinuation of study drug administration.. Non-serious events are listed at a 5.0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AA4500 0.58 mg | — | 1/16 (6.3%) | 16/16 (100%) |
| Event | AA4500 0.58 mg |
|---|---|
| Tendon ruptureInjury, poisoning and procedural complications | 1/16 |
| Event | AA4500 0.58 mg |
|---|---|
| Injection site haemorrhageGeneral disorders | 15/16 |
| Injection site swellingGeneral disorders | 14/16 |
| Injection site painGeneral disorders | 13/16 |
| HypertensionVascular disorders | 2/16 |
| ParaesthesiaNervous system disorders | 2/16 |
| BlisterSkin and subcutaneous tissue disorders | 1/16 |
| Blood urine presentInvestigations | 1/16 |
| Burning sensationNervous system disorders | 1/16 |
| ContusionInjury, poisoning and procedural complications | 1/16 |
| Food poisoningGastrointestinal disorders | 1/16 |
| Age, Categorical(Participants) | AA4500 0.58 mg |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 12 |
| >=65 years | 4 |
| Age, Continuous(years) | AA4500 0.58 mg |
|---|---|
| Mean | 60.6 ± 11.74 |
| Sex: Female, Male(Participants) | AA4500 0.58 mg |
|---|---|
| Female | 1 |
| Male | 15 |
| Race/Ethnicity, Customized(participants) | AA4500 0.58 mg |
|---|---|
| Black or African American | 1 |
| White | 14 |
| Other | 1 |
| Region of Enrollment(participants) | AA4500 0.58 mg |
|---|---|
| United States | 16 |
The record gives a start of Sep 2007, a primary completion of Dec 2007 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2012, 4 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Microbial Collagenase